Per 21 CFR 1271.155, an HCT/P establishment may request an exemption or alternative procedure to any Donor Eligibility and/or Current Good Tissue Practices regulation. The request for exemption or alternative procedure must be submitted to the appropriate center director at the FDA; however, CBER has redelegated the authority to issue a response to the director and deputy director of the Office of Cellular, Tissue and Gene Therapies. The request must include supporting documentation, including all relevant valid scientific data, and must contain either information justifying the requested exemption from the requirement or a description of a proposed alternative method of meeting the requirement. Additional information on requesting an exemption or alternative procedure is available.
AABB to Present on CGT Quality Gaps at Meeting on the Mesa
September 08, 2026
AABB Accepting Lightning Talk Proposals for Cord Blood Connect 2026 Through Tuesday
September 02, 2026
New CTMC Review Highlights Key Advances in Transfusion Medicine and Biotherapies From 2025
September 01, 2026